Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 18/20 | 0.55 |
| ▸ | CASP7 | P55210 | 2/20 | 0.49 |
| ▸ | CASP9 | P55211 | 2/20 | 0.49 |
| ▸ | CASP6 | P55212 | 2/20 | 0.49 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29384302 | 0.90 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL4466395 | 0.90 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL26071633 | 0.90 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL24213871 | 0.87 | CASP3 (0.56) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL17494194 | 0.87 | CASP3 (0.56) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL14646635 | 0.87 | CASP3 (0.56) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL29043505 | 0.82 | CASP3 (0.57) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL30376490 | 0.82 | CASP3 (0.57) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL10084325 | 0.81 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL23269036 | 0.81 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080199454-A1 | Phospholipid covalently linked to caspase inhibitor, such that the active group is released at the required site of disease such as inflammatory and degenerative diseases | MORTIMORE MICHAEL | 2008-08-21 | — | — | US | disclosed |
| US-20080199454-A1 | Phospholipid covalently linked to caspase inhibitor, such that the active group is released at the required site of disease such as inflammatory and degenerative diseases | MORTIMORE MICHAEL | 2008-08-21 | — | — | US | disclosed |
| US-7410956-B2 | Caspase inhibitor prodrugs | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-12 | — | — | US | disclosed |
| US-7410956-B2 | Caspase inhibitor prodrugs | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-12 | — | — | US | disclosed |
| WO-2003068242-A1 | PHOSPHOLIPIDS AS CASPASE INHIBITOR PRODRUGS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080199454-A1 | Phospholipid covalently linked to caspase inhibitor, such that the active group is released at the required site of disease such as inflammatory and degenerative diseases | CASP1, CASP5, CASP2 | CASP3 5/4885CASP7 6/4885CASP9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.